Drug Profile
Research programme: radiolabeled seprase inhibitors - Molecular Insight Pharmaceuticals
Alternative Names: Iodine-123 radiolabeled MIP-1232; MIP-1231; MIP-1232; MIP-1233Latest Information Update: 20 Feb 2019
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Class Benzamides; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
- 20 Aug 2009 Preclinical trials in Cancer in USA (unspecified route)